Total Payments
$734,512
2024 Payments
$190,163
Companies
24
Transactions
347
Medicare Patients
5,023
Medicare Billing
$14.3M
Payment Breakdown by Category
Consulting$314,879 (42.9%)
Research$234,740 (32.0%)
Other$130,918 (17.8%)
Travel$44,909 (6.1%)
Food & Beverage$8,962 (1.2%)
Education$104.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $314,879 | 61 | 42.9% |
| Unspecified | $234,740 | 36 | 32.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $98,488 | 36 | 13.4% |
| Travel and Lodging | $44,909 | 46 | 6.1% |
| Honoraria | $32,328 | 11 | 4.4% |
| Food and Beverage | $8,962 | 154 | 1.2% |
| Education | $104.59 | 2 | 0.0% |
| Grant | $102.66 | 1 | 0.0% |
Payments by Type
General
$499,772
311 transactions
Research
$234,740
36 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $262,426 | 102 | $0 (2024) |
| GlaxoSmithKline, LLC. | $211,695 | 13 | $0 (2024) |
| Amgen Inc. | $65,166 | 72 | $0 (2022) |
| IGI Inc | $45,326 | 13 | $0 (2024) |
| Takeda Pharmaceuticals International, Inc. | $34,809 | 9 | $0 (2019) |
| Karyopharm Therapeutics Inc. | $31,701 | 23 | $0 (2024) |
| Janssen Biotech, Inc. | $28,378 | 44 | $0 (2024) |
| PFIZER INC. | $20,421 | 18 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $10,613 | 12 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $7,422 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $190,163 | 45 | GlaxoSmithKline, LLC. ($112,525) |
| 2023 | $108,391 | 26 | GlaxoSmithKline, LLC. ($84,175) |
| 2022 | $24,032 | 25 | Karyopharm Therapeutics Inc. ($8,298) |
| 2021 | $10,782 | 6 | Amgen Inc. ($5,850) |
| 2020 | $30,035 | 15 | GlaxoSmithKline, LLC. ($12,820) |
| 2019 | $59,259 | 57 | Takeda Pharmaceuticals International, Inc. ($23,599) |
| 2018 | $108,739 | 81 | Celgene Corporation ($58,340) |
| 2017 | $203,110 | 92 | Celgene Corporation ($187,409) |
All Payment Transactions
347 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Celgene Corporation | ABECMA (Biological) | Food and Beverage | Cash or cash equivalent | $92.58 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $103.34 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $86.35 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $448.47 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $132.14 | General |
| Category: Oncology | ||||||
| 11/14/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,500.00 | Research |
| Study: ISB 1442-101 | ||||||
| 11/14/2024 | IGI Inc | — | — | Cash or cash equivalent | $3,500.00 | Research |
| Study: ISB 1442-101 | ||||||
| 11/14/2024 | IGI Inc | — | — | Cash or cash equivalent | $1,701.00 | Research |
| Study: ISB 1442-101 | ||||||
| 11/14/2024 | IGI Inc | — | — | Cash or cash equivalent | $500.00 | Research |
| Study: ISB 1442-101 | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,342.50 | General |
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $47.81 | General |
| 11/07/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $79.27 | General |
| Category: Oncology | ||||||
| 10/28/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $11,025.00 | General |
| 10/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $134.99 | General |
| 10/15/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $29.40 | General |
| 09/18/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| 06/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: Oncology | ||||||
| 06/11/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $62.37 | General |
| Category: Oncology | ||||||
| 06/10/2024 | Legend Biotech USA Inc. | — | Travel and Lodging | In-kind items and services | $25.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-4047-MM-007 | Celgene Corporation | $138,800 | 1 |
| ISB 1442-101 | IGI Inc | $45,326 | 13 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $34,600 | 1 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,820 | 13 |
| ELREXFIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,820 | 1 |
| A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation SCT | Takeda Pharmaceuticals U.S.A., Inc. | $1,750 | 1 |
| ACE-MM-200 | Celgene Corporation | $417.00 | 1 |
| RV-MM-PI-0458 | Celgene Corporation | $417.00 | 1 |
| Modified Kd56 Regimen in US Community Centers | Amgen Inc. | $414.18 | 2 |
| CC-5013-MM-026 | Celgene Corporation | $200.00 | 1 |
| Supervivencia global de pacientes con mieloma multiple en recaida o refractario tratados con carfilzomib | Amgen Inc. | $175.65 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,032 | 103,505 | $10.0M | $3.1M |
| 2022 | 30 | 1,370 | 167,845 | $14.6M | $4.9M |
| 2021 | 25 | 1,220 | 112,954 | $9.6M | $3.5M |
| 2020 | 30 | 1,401 | 71,221 | $8.1M | $2.8M |
Total Patients
5,023
Total Services
455,525
Medicare Billing
$14.3M
Procedure Codes
105
All Medicare Procedures & Services
105 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 42 | 48,420 | $5.3M | $1.8M | 34.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 54 | 13,341 | $1.1M | $455,489 | 40.2% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 45 | 6,590 | $626,050 | $248,384 | 39.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 44 | 8,401 | $353,322 | $154,969 | 43.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 173 | 909 | $499,950 | $141,437 | 28.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 59 | 671 | $201,300 | $46,879 | 23.3% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 26 | 11,219 | $1.2M | $45,536 | 3.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 346 | $147,050 | $39,484 | 26.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 13 | 11,100 | $111,000 | $26,442 | 23.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 61 | 372 | $96,720 | $22,874 | 23.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 103 | $58,195 | $12,839 | 22.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 183 | 1,121 | $39,235 | $9,391 | 23.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 58 | 432 | $43,200 | $8,303 | 19.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 110 | $27,500 | $7,865 | 28.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $18,900 | $5,319 | 28.1% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 16 | 17 | $10,200 | $2,817 | 27.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 17 | 68 | $10,200 | $1,852 | 18.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 23 | $8,050 | $1,845 | 22.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 57 | 127 | $12,700 | $1,669 | 13.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 108 | $10,800 | $1,582 | 14.6% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2022 | 47 | 59,040 | $6.2M | $2.1M | 34.4% |
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg | Office | 2022 | 13 | 23,600 | $2.4M | $815,080 | 34.5% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 47 | 15,840 | $1.3M | $523,962 | 38.9% |
| J9041 | Injection, bortezomib (velcade), 0.1 mg | Office | 2022 | 26 | 10,170 | $1.1M | $315,018 | 29.5% |
| J9047 | Injection, carfilzomib, 1 mg | Office | 2022 | 13 | 8,119 | $771,305 | $272,377 | 35.3% |
About Dr. Ruben Niesvizky, MD
Dr. Ruben Niesvizky, MD is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710074885.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruben Niesvizky, MD has received a total of $734,512 in payments from pharmaceutical and medical device companies, with $190,163 received in 2024. These payments were reported across 347 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($314,879).
As a Medicare-enrolled provider, Niesvizky has provided services to 5,023 Medicare beneficiaries, totaling 455,525 services with total Medicare billing of $14.3M. Data is available for 4 years (2020–2023), covering 105 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 10/09/2006
- Last Updated 07/31/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1710074885
Products in Payments
- Pomalyst (Drug) $173,992
- Revlimid (Drug) $62,462
- Kyprolis (Biological) $39,612
- XPOVIO (Drug) $31,701
- DARZALEX (Biological) $28,514
- ELREXFIO (Drug) $13,600
- NINLARO (Drug) $10,832
- Kyprolis (Drug) $9,700
- TECVAYLI (Biological) $6,204
- Blincyto (Biological) $5,249
- EMPLICITI (Biological) $5,094
- Aranesp (Biological) $4,555
- BLENREP (Biological) $3,475
- TAZVERIK (Drug) $2,363
- Ninlaro (Drug) $1,750
- Cellsearch (Device) $500.00
- ACY-241 (Drug) $417.00
- DARZALEX (Drug) $359.27
- TALVEY (Biological) $219.68
- Imbruvica (Drug) $188.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205
Dr. Ajai Chari, M.d, M.D
Hematology & Oncology — Payments: $536,082
Hematology & Oncology $536,082